GTx, Inc. Announces Release of Quarterly Financial Results, Conference Call and Webcast

MEMPHIS, TENNESSEE., April 7,2004 — GTx, Inc. (Nasdaq: GTXI), a biopharmaceutical company dedicated to the development and commercialization of therapeutic products for men¹s health, today announced that it will host a conference call and webcast to discuss 2004 first quarter financial results on Monday, April 19, 2004 at 10:30 a.m., Eastern Time. The call and webcast will follow the release of 2004 first quarter financial results earlier that day.

To listen to the conference call, please dial 800-915-4836 from the United States or Canada or 973 317-5319 from outside North America. A playback of the call will be available on April 19, 2004 from approximately 1:00 p.m., Eastern Time, through April 26, 2004 and may be accessed by dialing 800-428-6051 from the United States or Canada or 973-428-6051 from outside North America, and referencing reservation number 349402. Additionally, you may access the live and subsequently archived webcast of the conference call from the Investor Relations section of our website at www.gtxinc.com.

About GTx
GTx is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics primarily related to the treatment of serious men's health conditions. GTx's drug discovery and development programs are focused on small molecules that selectively modulate the effects of estrogens and androgens. GTx currently has two product candidates that are in human clinical trials. The company is currently conducting clinical trials on ACAPODENE™ (Toremifene Citrate) tablets, its most advanced product candidate, for two separate indications: (1) a Phase IIb clinical trial to assess the effect of toremifene in the reduction in the incidence of prostate cancer in men with precancerous prostate lesions and (2) a pivotal Phase III clinical trial to assess the effect of toremifene in the treatment of serious side effects of advanced prostate cancer therapy. GTx is initially developing its second product candidate, andarine, for the treatment of muscle wasting weight loss, or cachexia, which occurs from various types of cancer and other chronic diseases.